Business
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma.\n\"Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global expertise in product commercialization. She has been instrumental in the development and approval of multiple drugs across several therapeutic areas, including blockbuster medicines like LIPITOR® and CRESTOR®,\" said Todd Harris, CEO of TYRA. \"Adele has a diversified background both as a pharmaceutical executive and board member, with a wealth of knowledge in growing oncology business units. Her experience in launching ORGOVYX® for prostate cancer will be particularly valuable as we plan for late-stage development of TYRA-300 in non-muscle invasive bladder cancer. We look forward to Adele's insights as we advance our precision medicine pipeline and continue to grow TYRA.\"\nMost recently, Ms. Gulfo served as Chief Executive Officer, Biopharma Commercial Unit, for Sumitomo Pharma America, Inc. where she led the commercial and development portfolio for multiple therapeutic areas including oncology, rare disease, urology, CNS and Women's Health. Previously, Ms. Gulfo served as chief commercial and business development officer at Sumitovant Biopharma from 2020 to 2023. Previously, she served as chief commercial development officer at Roivant Sciences, where she was influential in the formation of Sumitovant and in preparations for the launches of key brands, including ORGOVYX® (prostate cancer), GEMTESA (overactive bladder), RETHYMIC (congenital athymia), and MYFEMBREE (women's health). Adele was the president and general manager of Pfizer's $12B+ U.S. primary care business unit, as well as country manager for Pfizer's U.S. Biopharma business, including specialty and oncology business units. Earlier in her career at Pfizer, Adele was instrument...